South Rampart Pharma: Funding, Investors & Team (Nov 2026)
South Rampart Pharma, Inc. is a biotech company in the clinical stage that focuses on developing a safe and efficient method of pain relief. Its main product, SRP-001, is a unique analgesic that targets pain signaling pathways in the midbrain's periaqueductal grey region. Unlike opioids, SRP-001 is non-addictive and does not pose a risk of abuse. Additionally, it does not have the liver toxicity associated with acetaminophen. In comparison to acetaminophen, SRP-001 offers similar pain relief properties without the risk of liver damage or kidney toxicity associated with NSAIDs. Early results from Phase 1 trials show that SRP-001 is safe, well-tolerated, and has promising pharmacokinetics. It has the potential to be a safer and more effective alternative to current pain medications.
South Rampart Pharma has raised $8.0M across 2 funding rounds on record, the most recent a Series A of $8.0M announced in May 2025.
That round is in line with the $8.8M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
South Rampart Pharma Company Profile and Key Stats
Latest funding round on record: May 2025.
South Rampart Pharma Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
South Rampart Pharma announced an undisclosed round in Sep 2023; the amount was not disclosed.
1.7 years later, a Series A of $8.0M was announced in May 2025.
South Rampart Pharma Founders and Leadership Team
Contact details for the South Rampart Pharma team: 1 of 1 has an email address on file.
Start 14-day free trial →South Rampart Pharma Funding Compared to Other Biotechnology Startups
South Rampart Pharma's latest round of $8.0M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like South Rampart Pharma in Biotechnology and New Orleans
Companies Similar to South Rampart Pharma
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates to target driver oncogenes.…
Arctic Therapeutics specializes in finding the genetic origins of common diseases and creating successful…
100XBIO is creating a cutting-edge platform for analyzing multiple T-cells automatically, aiming to…
MEND is a company focused on life sciences, determined to assist individuals in achieving better health…
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
South Rampart Pharma Funding FAQs
What does South Rampart Pharma do?
South Rampart Pharma, Inc. is a biotech company in the clinical stage that focuses on developing a safe and efficient method of pain relief. Its main product, SRP-001, is a unique analgesic that targets pain signaling pathways in the midbrain's periaqueductal grey region. Unlike opioids, SRP-001 is non-addictive and does not pose a risk of abuse. Additionally, it does not have the liver toxicity associated with acetaminophen. In comparison to acetaminophen, SRP-001 offers similar pain relief properties without the risk of liver damage or kidney toxicity associated with NSAIDs. Early results from Phase 1 trials show that SRP-001 is safe, well-tolerated, and has promising pharmacokinetics. It has the potential to be a safer and more effective alternative to current pain medications.
How much funding has South Rampart Pharma raised?
South Rampart Pharma has raised $8.0M across 2 rounds on record. The most recent is a Series A of $8.0M announced in May 2025.
When did South Rampart Pharma last raise funding?
South Rampart Pharma's most recent funding round on record is a Series A of $8.0M, announced in May 2025.
Who founded South Rampart Pharma?
FundedIQ lists Hernan Bazan (Founder) at South Rampart Pharma.
Where is South Rampart Pharma headquartered?
South Rampart Pharma is based in New Orleans, Louisiana, United States.
How many employees does South Rampart Pharma have?
South Rampart Pharma is in the 1-10 employee band.
How does South Rampart Pharma's funding compare to other Biotechnology startups?
South Rampart Pharma's latest round of $8.0M is in line with the $8.8M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's South Rampart Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for South Rampart Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.